Citable filing context
EL's research view summarizes recent SEC filing context, starting with earnings from Aug 19, 2026.
| Filed | Item | Context |
|---|---|---|
| Aug 19, 2026 | earnings | Estée Lauder reported fiscal 2026 fourth-quarter and full-year results, with net sales increasing 5% to $15.0 billion. |
| Jul 24, 2026 | management_change | Director Jennifer Hyman will retire from the Board of Directors effective November 16, 2026. |
| Jul 7, 2026 | restructuring | Estée Lauder updated its restructuring program, expecting cumulative charges of approximately $1.75 billion through June 30, 2026. |
| Aug 19, 2026 | Guidance: adjusted_constant_currency_eps | 3.06 to 3.31 |
| Aug 19, 2026 | Guidance: adjusted_effective_tax_rate | 33.00 to 34.00 |
| Aug 19, 2026 | Guidance: adjusted_eps | 3.10 to 3.35 |
| Aug 19, 2026 | business | The Estée Lauder Companies Inc. operates as a global leader in prestige beauty, manufacturing and marketing products across skin care, makeup, fragrance, and hair care. Its portfolio features major owned brands—including Estée Lauder, Clinique, M·A·C, La Mer, Jo Malone London, TOM FORD, Aveda, Le Labo, Too Faced, Dr.Jart+, and The Ordinary—as well as licensed beauty lines such as AERIN and Balmain. Distribution spans department stores, travel retail, specialty-multi retailers, freestanding stores, and direct-to-consumer digital platforms. In fiscal 2026, net sales reached $15.05 billion, distributed across the Americas ($4.46 billion), Europe/EUKEM ($3.79 billion), Asia/Pacific ($3.75 billion), and Mainland China ($3.06 billion). To rebuild profit margins and streamline operations, the company is executing its Profit Recovery and Growth Plan (PRGP). This multi-year restructuring program entails approximately 10,000 net job reductions globally and total estimated pre-tax charges of $1.75 billion ($1.43 billion incurred through fiscal 2026). Recent financial performance has been impacted by demand headwinds in Asia travel retail and mainland China, resulting in intangible asset and goodwill impairments across key acquisitions, including TOM FORD, Too Faced, and Dr.Jart+. To support ongoing transformation and working capital needs, the company maintains $3.5 billion in committed revolving credit facilities. |
| Aug 19, 2026 | mda | For fiscal 2026, net sales increased 5% (3% in constant currency) to $15.05 billion. Operating income rebounded to $780 million from an operating loss of $785 million in fiscal 2025, driving diluted EPS to $0.50 compared to a prior-year loss of $3.15, while adjusted EPS rose 66% to $2.51. Performance was anchored by Skin Care ($7.34 billion net sales) and Fragrance ($2.78 billion net sales, up 10% in constant currency), benefiting from gross margin expansion, execution of the Profit Recovery and Growth Plan (PRGP), and the non-recurrence of $1.29 billion in prior-year impairment charges on Dr.Jart+, TOM FORD, and Too Faced. Geographically, Mainland China led growth with constant currency net sales up 9% to $3.06 billion and operating income rising 92% to $373 million, recovering from fiscal 2025 travel retail headwinds and North American retail destocking. Operating results were impacted by an $84 million securities class action litigation settlement in fiscal 2026 and a $159 million talcum litigation settlement charge in fiscal 2025. The reported effective tax rate surged to 64.8%, driven by foreign valuation allowances and tax law adjustments. EL ended the period with $3.50 billion in cash and cash equivalents, though credit ratings retain negative outlooks (A-/A3) amid monitoring of global tariffs. |
Source: SEC EDGAR filing text and events; period Aug 19, 2026; filed Aug 19, 2026.
EL company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.